Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
12 studies found for:    ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY
Show Display Options
Rank Status Study
1 Active, not recruiting Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency.
Conditions: Adrenal Hyperplasia, Congenital;   21-hydroxylase Deficiency
Intervention: Other: Functional explorations
2 Completed A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency
Condition: 21-hydroxylase Deficiency
Intervention: Drug: Abiraterone acetate
3 Completed Examining Genetic Differences Among People With 21-Hydroxylase Deficiency
Condition: 21-hydroxylase Deficiency
Intervention: Procedure: Hydrocortisone withdrawal
4 Unknown  Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers
Condition: Adrenal Hyperplasia, Congenital
Intervention:
5 Completed Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia
Condition: Congenital Adrenal Hyperplasia
Intervention:
6 Unknown  Role of the Protein Osteoprotegerin in the Bone Health of Women With Congenital Adrenal Hyperplasia
Condition: Adrenal Hyperplasia, Congenital
Intervention:
7 Completed
Has Results
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
Conditions: Congenital Adrenal Hyperplasia;   21-Hydroxylase Deficiency;   Adrenogenital Syndrome
Interventions: Drug: Chronocort;   Drug: Cortef
8 Not yet recruiting Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1
Condition: Congenital Adrenal Hyperplasia
Intervention: Drug: Abiraterone acetate
9 Recruiting A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Condition: Congenital Adrenal Hyperplasia
Intervention: Drug: ATR-101
10 Active, not recruiting Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
Conditions: Congenital Adrenal Hyperplasia;   Growth Disorder
Interventions: Drug: Flutamide and Testolactone;   Drug: Deslorelin
11 Withdrawn Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
Condition: Congenital Adrenal Hyperplasia
Intervention: Drug: NBI-77860
12 Completed SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan.
Condition: Hyperaldosteronism
Intervention: Other: Ct-scan or adrenal vein sampling

Study has passed its completion date and status has not been verified in more than two years.